1. Home
  2. RWAY vs TECX Comparison

RWAY vs TECX Comparison

Compare RWAY & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Runway Growth Finance Corp.

RWAY

Runway Growth Finance Corp.

HOLD

Current Price

$8.85

Market Cap

338.2M

Sector

N/A

ML Signal

HOLD

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$24.37

Market Cap

366.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RWAY
TECX
Founded
2015
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Sector
Exchange
Nasdaq
Nasdaq
Market Cap
338.2M
366.8M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
RWAY
TECX
Price
$8.85
$24.37
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$11.08
$80.40
AVG Volume (30 Days)
333.0K
284.0K
Earning Date
03-19-2026
03-19-2026
Dividend Yield
15.82%
N/A
EPS Growth
44.67
N/A
EPS
1.48
N/A
Revenue
$141,071,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.74
N/A
P/E Ratio
$5.97
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.35
$13.70
52 Week High
$11.73
$47.35

Technical Indicators

Market Signals
Indicator
RWAY
TECX
Relative Strength Index (RSI) 42.10 64.77
Support Level $8.61 $21.33
Resistance Level $9.31 $24.53
Average True Range (ATR) 0.18 1.81
MACD -0.04 0.43
Stochastic Oscillator 40.72 71.46

Price Performance

Historical Comparison
RWAY
TECX

About RWAY Runway Growth Finance Corp.

Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and UK, Canada, Netherlands, with the majority of its portfolio invested in the United States.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: